449 related articles for article (PubMed ID: 38670230)
1. Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin.
Shah SA; Oakes RS; Jewell CM
Adv Drug Deliv Rev; 2024 Jun; 209():115315. PubMed ID: 38670230
[TBL] [Abstract][Full Text] [Related]
2. Advances in immunotherapy delivery from implantable and injectable biomaterials.
Leach DG; Young S; Hartgerink JD
Acta Biomater; 2019 Apr; 88():15-31. PubMed ID: 30771535
[TBL] [Abstract][Full Text] [Related]
3. Self-Assembly as a Molecular Strategy to Improve Immunotherapy.
Froimchuk E; Carey ST; Edwards C; Jewell CM
Acc Chem Res; 2020 Nov; 53(11):2534-2545. PubMed ID: 33074649
[TBL] [Abstract][Full Text] [Related]
4. Biomaterials as Local Niches for Immunomodulation.
Adu-Berchie K; Mooney DJ
Acc Chem Res; 2020 Sep; 53(9):1749-1760. PubMed ID: 32786230
[TBL] [Abstract][Full Text] [Related]
5. Improving Vaccine and Immunotherapy Design Using Biomaterials.
Bookstaver ML; Tsai SJ; Bromberg JS; Jewell CM
Trends Immunol; 2018 Feb; 39(2):135-150. PubMed ID: 29249461
[TBL] [Abstract][Full Text] [Related]
6. Exploiting Unique Features of Microneedles to Modulate Immunity.
Edwards C; Shah SA; Gebhardt T; Jewell CM
Adv Mater; 2023 Dec; 35(52):e2302410. PubMed ID: 37380199
[TBL] [Abstract][Full Text] [Related]
7. Biomaterial Strategies for Selective Immune Tolerance: Advances and Gaps.
Carey ST; Bridgeman C; Jewell CM
Adv Sci (Weinh); 2023 Mar; 10(8):e2205105. PubMed ID: 36638260
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial drug delivery approaches for immunomodulation.
Stewart JM; Keselowsky BG
Adv Drug Deliv Rev; 2017 May; 114():161-174. PubMed ID: 28532690
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of Immunotherapies in Head and Neck Cancers Using Biomaterial-Based Treatment Strategies.
Sunga GM; Hartgerink J; Sikora AG; Young S
Tissue Eng Part C Methods; 2023 Jun; 29(6):257-275. PubMed ID: 37183412
[TBL] [Abstract][Full Text] [Related]
10. Harnessing Biomaterials to Study and Direct Antigen-Specific Immunotherapy.
Edwards C; Carey ST; Jewell CM
ACS Appl Bio Mater; 2023 Jun; 6(6):2017-2028. PubMed ID: 37068126
[TBL] [Abstract][Full Text] [Related]
11. Biomaterial Strategies for Immunomodulation.
Hotaling NA; Tang L; Irvine DJ; Babensee JE
Annu Rev Biomed Eng; 2015; 17():317-49. PubMed ID: 26421896
[TBL] [Abstract][Full Text] [Related]
12. Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells.
Desai N; Hasan U; K J; Mani R; Chauhan M; Basu SM; Giri J
Acta Biomater; 2023 Apr; 161():1-36. PubMed ID: 36907233
[TBL] [Abstract][Full Text] [Related]
13. Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.
Ruan S; Huang Y; He M; Gao H
Adv Sci (Weinh); 2022 May; 9(16):e2200027. PubMed ID: 35343112
[TBL] [Abstract][Full Text] [Related]
14. Mapping the Mechanical and Immunological Profiles of Polymeric Microneedles to Enable Vaccine and Immunotherapy Applications.
Shah SA; Oakes RS; Kapnick SM; Jewell CM
Front Immunol; 2022; 13():843355. PubMed ID: 35359943
[TBL] [Abstract][Full Text] [Related]
15. Delivery strategies of cancer immunotherapy: recent advances and future perspectives.
Zhao Z; Zheng L; Chen W; Weng W; Song J; Ji J
J Hematol Oncol; 2019 Nov; 12(1):126. PubMed ID: 31779642
[TBL] [Abstract][Full Text] [Related]
16. Tissue-Targeted Drug Delivery Strategies to Promote Antigen-Specific Immune Tolerance.
Rui Y; Eppler HB; Yanes AA; Jewell CM
Adv Healthc Mater; 2023 Jan; 12(6):e2202238. PubMed ID: 36417578
[TBL] [Abstract][Full Text] [Related]
17. Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy.
Isser A; Livingston NK; Schneck JP
Biomaterials; 2021 Jan; 268():120584. PubMed ID: 33338931
[TBL] [Abstract][Full Text] [Related]
18. Recent Biomaterial-Assisted Approaches for Immunotherapeutic Inhibition of Cancer Recurrence.
Mozafari N; Jahanbekam S; Ashrafi H; Shahbazi MA; Azadi A
ACS Biomater Sci Eng; 2024 Mar; 10(3):1207-1234. PubMed ID: 38416058
[TBL] [Abstract][Full Text] [Related]
19. Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy.
Calmeiro J; Carrascal M; Gomes C; Falcão A; Cruz MT; Neves BM
J Immunother Cancer; 2019 Sep; 7(1):238. PubMed ID: 31484548
[TBL] [Abstract][Full Text] [Related]
20. Harnessing biomaterials to engineer the lymph node microenvironment for immunity or tolerance.
Andorko JI; Hess KL; Jewell CM
AAPS J; 2015 Mar; 17(2):323-38. PubMed ID: 25533221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
